Show simple item record

dc.contributor.authorLerata, Mookho S.
dc.contributor.authorD’Souza, Sarah
dc.contributor.authorSibuyi, Nicole Remaliah Samantha
dc.date.accessioned2021-01-25T13:13:44Z
dc.date.available2021-01-25T13:13:44Z
dc.date.issued2020
dc.identifier.citationLerata, M. S. et al. (2020). Encapsulation of variabilin in stearic acid solid lipid nanoparticles enhances its anticancer activity in vitro. Molecules, 25(4),830en_US
dc.identifier.issn1420-3049
dc.identifier.uri10.3390/molecules25040830
dc.identifier.urihttp://hdl.handle.net/10566/5757
dc.description.abstractThe use of natural products as chemotherapeutic agents is well established; however, many of these are associated with undesirable side effects, including high toxicity and instability. Furthermore, the development of drug resistant cancers makes the search for new anticancer lead compounds a priority. In this study, the extraction of an Ircinia sp. sponge resulted in the isolation of an inseparable mixture of (7E,12E,20Z)-variabilin (1) and (7E,12Z,20Z)-variabilin (2) and structural assignment was established using standard 1D and 2D NMR experiments. The cytotoxic activity of the compound against three solid tumour cell lines displayed moderate anti-cancer activity through apoptosis, together with a general lack of selectivity among the cancer cell lines studied. Structural assignment and cytotoxic evaluation of variabilin was complicated and further aggravated by its inherent instability. Variabilin was therefore incorporated into solid lipid nanoparticles (SLNs) and the stability and cytotoxic activity evaluated. Encapsulation of variabilin into SLNs led to a marked improvement in stability of the natural product coupled with enhanced cytotoxic activity, particularly against the prostate (PC-3) cancer cell line, with IC50 values of 87.74 µM vs. 8.94 µM for the variabilin alone and Var-SLN, respectively. Both variabilin and Var-SLN revealed comparable activity to Ceramide against the MCF-7 breast cancer cell line, revealing IC50 values of 34.8, 38.1 and 33.6 µM for variabilin, Var-SLN and Ceramide, respectively.en_US
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.subjectAnti-cancer activityen_US
dc.subjectMarine natural productsen_US
dc.subjectSolid lipid nanoparticlesen_US
dc.subjectSpongeen_US
dc.subjectVariabilinen_US
dc.titleEncapsulation of variabilin in stearic acid solid lipid nanoparticles enhances its anticancer activity in vitroen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record